Arthur Taveras - 04 Oct 2024 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Reporting relationship: Chief Scientific Officer
Issuer ticker: XFOR
Reported as of: 04 Oct 2024
Net transaction value: -$43,306
SEC form: 4
Accepted by SEC: 08 Oct 2024, 16:44:02 UTC
Prior SEC filing: 11 Mar 2024
Source filing: View source filing
Reporting owner signature: /s/ Adam S. Mostafa, attorney-in-fact

Key filing fact

Arthur Taveras filed Form 4 for X4 Pharmaceuticals, Inc (XFOR) on 08 Oct 2024.

Key facts

This page summarizes Arthur Taveras's Form 4 filing for X4 Pharmaceuticals, Inc (XFOR).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 08 Oct 2024, 16:44.

Change

Previous filing in this sequence was filed on 11 Mar 2024.
Current net transaction value: -$43,306.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XFOR transaction

Common Stock

Award

Transaction value: $0
Shares: +230,645
Change %: +98%
Price: $0.000000
Shares after: 464,946
Date: 04 Oct 2024
Ownership: Direct
Footnotes: F1

XFOR transaction

Common Stock

Sale

Transaction value: $43,306
Shares: -76,920
Change %: -17%
Price: $0.5630
Shares after: 388,026
Date: 07 Oct 2024
Ownership: Direct
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition.

Footnote F2

These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.5291 to $0.6038, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.